2023
Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial
Morais A, Locascio J, Sansing L, Lamb J, Nagarkatti K, Imai T, van Leyen K, Aronowski J, Koenig J, Bosetti F, Lyden P, Ayata C, Bosetti F, Koenig J, Lyden P, Lamb J, Nagarkatti K, Hess D, Kamat P, Khan M, Dhandapani K, Arbab A, Siddiqui S, Smith C, Nisar M, Leira E, Chauhan A, Dhanesha N, Patel R, Kumskova M, Thedens D, Wang K, Ayata C, Morais A, Imai T, Qin T, Jin X, Erdogan T, Yu L, Mandeville J, Kimberly W, Whittier J, Lo E, Arai K, Van Leyen K, Sansing L, Hyder F, Mihailovic J, Sanganahalli B, Diaz-Perez S, Velazquez S, Beatty H, Johnson C, Herman A, Boisserand L, Immakavar E, Koehler R, Dawson T, Dawson V, Shi Y, Avery B, Lannon S, Bibic A, Akhter K, Karuppagounder S, Aronowski J, McCullough L, Obertas L, Goh A, Huang S, Chauhan A. Embracing Heterogeneity in The Multicenter Stroke Preclinical Assessment Network (SPAN) Trial. Stroke 2023, 54: 620-631. PMID: 36601951, PMCID: PMC9870939, DOI: 10.1161/strokeaha.122.040638.Peer-Reviewed Original ResearchConceptsTotal anesthesia durationAnesthesia durationIndependent predictorsMultivariable analysisClinical trialsTransient focal cerebral ischemiaFocal cerebral ischemiaCerebral blood flowLaser Doppler flowCentralized randomizationModified intentionTreat populationExperimental strokeCerebral ischemiaDoppler flowRodent modelsMCAOBlood flowNetwork trialFlow dropPreclinical trialsMouse cohortsStudy designTrialsTrial onset
2013
β-Blockers associated with no class-specific survival benefit in acute intracerebral hemorrhage
Shoup JP, Winkler J, Czap A, Staff I, Fortunato G, McCullough LD, Sansing LH. β-Blockers associated with no class-specific survival benefit in acute intracerebral hemorrhage. Journal Of The Neurological Sciences 2013, 336: 127-131. PMID: 24183854, PMCID: PMC4956481, DOI: 10.1016/j.jns.2013.10.022.Peer-Reviewed Original ResearchConceptsΒ-blocker treatmentΒ-blocker useBlood pressure controlAcute intracerebral hemorrhageIntracerebral hemorrhageAdrenergic antagonistsAntihypertensive therapyPressure controlInflammation-induced injuryΒ-blocker therapyDatabase of patientsSympathetic nervous systemSpontaneous intracerebral hemorrhageAntihypertensive treatmentInpatient deathSurvival benefitImproved survivalOngoing trialsMultivariable analysisICH patientsImmune activationInpatient stayRetrospective analysisStudy populationΒ-blockers
2009
Prior antiplatelet use does not affect hemorrhage growth or outcome after ICHSYMBOL
Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner SE. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICHSYMBOL. Neurology 2009, 72: 1397-1402. PMID: 19129506, PMCID: PMC2677505, DOI: 10.1212/01.wnl.0000342709.31341.88.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrainBrain EdemaCausalityCerebral HemorrhageDisease ProgressionDrug-Related Side Effects and Adverse ReactionsFemaleHumansIatrogenic DiseaseImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedOutcome Assessment, Health CarePlatelet Aggregation InhibitorsProspective StudiesTomography, X-Ray ComputedTreatment OutcomeConceptsAntiplatelet medication useAntiplatelet medicationsIntracerebral hemorrhageSpontaneous intracerebral hemorrhageHemorrhage expansionMedication useClinical outcomesICH onsetHemorrhage growthTime of ICHVolume of ICHInitial ICH volumeIntracerebral hemorrhage onsetPrior antiplatelet usePlacebo-controlled trialRecent clinical trialsAssociation of useGrowth of ICHAntiplatelet useEdema growthOral anticoagulationRankin scorePlacebo armCerebral hemorrhageMultivariable analysis